Abstract:Background: Glioblastoma is the most common type of brain cancer, with a prognosis that is unfortunately poor. Despite considerable progress in the field, the intricate molecular basis of this cancer remains elusive. Aim: The aim of this study was to identify genetic indicators of glioblastoma and reveal the processes behind its development. Objective: The advent and integration of supercomputing technology have led to a significant advancement in gene expression analysis platforms. Microarray analysis has gained recognition for its pivotal role in oncology, crucial for the molecular categorization of tumors, diagnosis, prognosis, stratification of patients, forecasting tumor responses, and pinpointing new targets for drug discovery. Numerous databases dedicated to cancer research, including the Gene Expression Omnibus (GEO) database, have been established. Identifying differentially expressed genes (DEGs) and key genes deepens our understanding of the initiation of glioblastoma, potentially unveiling novel markers for diagnosis and prognosis, as well as targets for the treatment of glioblastoma. Methods: This research sought to discover genes implicated in the development and progression of glioblastoma by analyzing microarray datasets GSE13276, GSE14805, and GSE109857 from the GEO database. DEGs were identified, and a function enrichment analysis was performed. Additionally, a protein-protein interaction network (PPI) was constructed, followed by module analysis using the tools STRING and Cytoscape. Results: The analysis yielded 88 DEGs, consisting of 66 upregulated and 22 downregulated genes. These genes' functions and pathways primarily involved microtubule activity, mitotic cytokinesis, cerebral cortex development, localization of proteins to the kinetochore, and the condensation of chromosomes during mitosis. A group of 27 pivotal genes was pinpointed, with biological process analysis indicating significant enrichment in activities, such as division of the nucleus during mitosis, cell division, maintaining cohesion between sister chromatids, segregation of sister chromatids during mitosis, and cytokinesis. The survival analysis indicated that certain genes, including PCNA clamp-associated factor (PCLAF), ribonucleoside- diphosphate reductase subunit M2 (RRM2), nucleolar and spindle-associated protein 1 (NUSAP1), and kinesin family member 23 (KIF23), could be instrumental in the development, invasion, or recurrence of glioblastoma. Conclusion: The identification of DEGs and key genes in this study advances our comprehension of the molecular pathways that contribute to the oncogenesis and progression of glioblastoma. This research provides valuable insights into potential diagnostic and therapeutic targets for glioblastoma.

Analysis of the key prognostic genes and potential traditional Chinese medicine therapeutic targets in glioblastoma based on bioinformatics and network pharmacology methods

Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme

Small molecule drug discovery for glioblastoma treatment based on bioinformatics and cheminformatics approaches

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme

Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma

Exploring the Therapeutic Mechanisms and Prognostic Targets of Biochanin A in Glioblastoma Via Network Pharmacology and Bioinformatics Analysis

Identification of biomarkers and ceRNA network in glioblastoma through bioinformatic analysis and evaluation of potential prognostic values

Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma

Development of an Immune-Related Prognostic Index Associated with Glioblastoma

Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experiments

Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme

Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification

Identification of Key Candidate Genes and Pathways in Glioblastoma by Integrated Bioinformatical Analysis

The Promising Novel Biomarkers and Candidate Small Molecule Drugs in Lower‐grade Glioma: Evidence from Bioinformatics Analysis of High‐throughput Data

Identification of Core Biomarkers Associated with Outcome in Glioma: Evidence from Bioinformatics Analysis.

Bioinformatics Analysis and Experimental Validation for Exploring Key Molecular Markers for Glioblastoma

Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis

Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis

Analysis of Differentially Expressed Genes Based on Microarray Data of Glioma.